Caribou Biosciences Files 8-K on Officer/Director Changes
Ticker: CRBU · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1619856
| Field | Detail |
|---|---|
| Company | Caribou Biosciences, INC. (CRBU) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $485,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election, filing
Related Tickers: CRBU
TL;DR
Caribou Bio leadership shakeup, new officers/directors elected, and compensation details filed.
AI Summary
On January 2, 2025, Caribou Biosciences, Inc. filed an 8-K report. The filing primarily concerns the departure of directors or certain officers, the election of directors, and the appointment of certain officers. It also includes information on compensatory arrangements for certain officers and a Regulation FD Disclosure. Additionally, the report contains financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the leadership and governance of Caribou Biosciences, which could impact the company's strategic direction and operational management.
Risk Assessment
Risk Level: medium — Changes in key personnel and board composition can signal strategic shifts or internal challenges, warranting closer observation.
Key Players & Entities
- Caribou Biosciences, Inc. (company) — Registrant
- January 2, 2025 (date) — Date of earliest event reported
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Are there any details on compensatory arrangements for officers?
Yes, the filing includes information on compensatory arrangements of certain officers.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on changes in directors/officers, elections, appointments, compensatory arrangements, and includes a Regulation FD Disclosure and financial statements/exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on January 2, 2025.
What is Caribou Biosciences, Inc.'s principal executive office address?
The principal executive offices are located at 2929 7th Street, Suite 105, Berkeley, California 94710.
Filing Stats: 1,490 words · 6 min read · ~5 pages · Grade level 11.3 · Accepted 2025-01-02 08:03:14
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CRBU NASDAQ Global
- $485,000 — e: (i) an initial annual base salary of $485,000 (the "Base Salary"); (ii) a discretiona
Filing Documents
- crbu-20250102.htm (8-K) — 34KB
- crbu-20250102xexx991.htm (EX-99.1) — 12KB
- high-resxsrixryalix123024a.jpg (GRAPHIC) — 356KB
- img25401123_0a.jpg (GRAPHIC) — 51KB
- 0001619856-25-000002.txt ( ) — 737KB
- crbu-20250102.xsd (EX-101.SCH) — 2KB
- crbu-20250102_lab.xml (EX-101.LAB) — 23KB
- crbu-20250102_pre.xml (EX-101.PRE) — 13KB
- crbu-20250102_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 2, 2025, the Company issued a press release regarding the appointment of Mr. Ryali as the Company's CFO. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01 of this Current Report on Form 8-K is being "furnished" and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act and shall not be incorporated or deemed to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Caribou Biosciences, Inc. on January 2, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Caribou Biosciences, Inc. Date: January 2, 2025 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer